/PRNewswire/ Data Bridge Market Research completed a qualitative study titled "Natural Killer (NK) Cell Therapeutics Market" with 100+ market data tables,.
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide
February 04, 2021 11:35 ET | Source: Alphageneron Pharmaceuticals Alphageneron Pharmaceuticals Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1
st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.
The autologous NK cell therapy redirects a patient’s NK cells to target a cell membrane form of Heat Shock Protein 70 (Hsp70) which has been discovered to be highly expressed on many cancer cells, but not on healthy cells. NK cells are harvested from the patient’s blood, activated
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For .
Alphageneron PharmaceuticalsFebruary 4, 2021 GMT
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.
The autologous NK cell therapy redirects a patient’s NK cells to target a cell membrane form of Heat Shock Protein 70 (Hsp70) which has been discovered to be highly expressed on many cancer cells, but not on healthy cells. NK cells are harvested from the patient’s blood, activated